BNC-210 is under clinical development by Bionomics and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase II drugs for Post-Traumatic Stress Disorder (PTSD) have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BNC-210’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BNC-210 overview
BNC-210 (IW-2143) is under development for the treatment of agitation (anxiety disorder), post-traumatic stress disorder, social anxiety disorder, unspecified CNS diseases and CCK-4 induced panic disorder. The drug candidate is administered through the oral route. BNC-210 acts by targeting neuronal acetylcholine receptor subunit alpha-7 (CHRNA7). It was also under development for the treatment of depression.
Bionomics overview
Bionomics, is a biopharmaceutical company that discovers and develops ion channel modulators for cancer, and central nervous system disorders such as anxiety, depression, and Alzheimer’s disease. The company’s pipeline products include BNC210, BNC 105, BNC101, and BNC375, among others. It uses various technology platforms including KV1.3 compound, VDA compound, MultiCore technology, and cancer stem cell technology platform for discovering highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells, among others. The company conducts clinical studies including post-traumatic stress disorder studies, multiple ascending dose studies, and generalized anxiety disorder studies, dose-escalation studies. Bionomics is headquartered in Eastwood, South Australia, Australia.
For a complete picture of BNC-210’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
